Response to the letter of Peng Bai and Jun Zhang on Cost-effectiveness of Adjuvant Alectinib in ALK-positive NSCLC-Considerations for Broader Applicability.

Supiot R; du Manoir de Juaye L; Chouaid C

doi:10.1016/j.lungcan.2026.108944

← 뒤로

Response to the letter of Peng Bai and Jun Zhang on Cost-effectiveness of Adjuvant Alectinib in ALK-positive NSCLC-Considerations for Broader Applicability.

0/5 보강

Lung cancer (Amsterdam, Netherlands) 📖 저널 OA 6.7% 2025~2026 2026 Vol.213() p. 108944

Supiot R, du Manoir de Juaye L, Chouaid C

ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 44.0%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도

PubMed ↗ DOI ↗ BibTeX ↓ RIS ↓

이 논문을 인용하기

↓ .bib ↓ .ris

APA Supiot R, du Manoir de Juaye L, Chouaid C (2026). Response to the letter of Peng Bai and Jun Zhang on Cost-effectiveness of Adjuvant Alectinib in ALK-positive NSCLC-Considerations for Broader Applicability.. Lung cancer (Amsterdam, Netherlands), 213, 108944. https://doi.org/10.1016/j.lungcan.2026.108944

MLA Supiot R, et al.. "Response to the letter of Peng Bai and Jun Zhang on Cost-effectiveness of Adjuvant Alectinib in ALK-positive NSCLC-Considerations for Broader Applicability.." Lung cancer (Amsterdam, Netherlands), vol. 213, 2026, pp. 108944.

PMID 41604756 ↗

DOI 10.1016/j.lungcan.2026.108944

같은 제1저자의 인용 많은 논문 (1)

Cost-effectiveness of adjuvant alectinib in the treatment of patients with resected stage IB-IIIA ALK-positive non-small lung cancer in France, based on the ALINA study.
Lung cancer (Amsterdam, Netherlands) 2026